文献速递传染病防控与疫情报告免疫规划

2025年9–12月北京H3N2 K亚分支流感疫苗有效性研究

Moderate protection from vaccination against influenza A(H3N2) subclade K in Beijing, China, September to December 2025.
PubMed 文献 · Euro Surveill · 2026-01-01

2025/26流感季早期,北京A(H3N2) K亚分支迅速流行。9579名参与者中,316份随机选取的A(H3N2)阳性样本测序显示84.8%为K亚分支,65株病毒抗原分析提示抗原漂移;调整后疫苗有效性为41.3%(95%CI:29.2–51.3),表明在K亚分支流行季有中等保护。

要点

  • K亚分支占测序阳性样本84.8%,存在抗原漂移。
  • 调整后疫苗有效性41.3%(95%CI:29.2–51.3),为中等保护。
  • 检测阴性设计纳入9579名流感样病例门诊患者。

核心结论

  • 尽管K亚分支流行且存在抗原漂移,流感疫苗仍提供中等保护,调整后VE为41.3%(95%CI:29.2–51.3)。

研究设计与样本

  • 对316份随机选取的A(H3N2)阳性样本测序,对65株病毒进行抗原分析。

主要发现

  • 316份随机选取的A(H3N2)阳性样本中84.8%为K亚分支。
  • 65株病毒抗原分析提示抗原漂移。
  • 调整后疫苗对实验室确诊流感的有效性为41.3%(95%CI:29.2–51.3)。

关键数值与推荐

  • 疫苗有效性(VE)估计值为41.3%(95%CI:29.2–51.3),对象为流感样病例门诊患者。

临床怎么用

  • 在K亚分支流行季,流感疫苗接种仍可提供中等保护,应继续推荐接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the early 2025/26 influenza season, influenza A(H3N2) subclade K rapidly predominated in Beijing, China. Using a test-negative design, we estimated influenza vaccine effectiveness (VE) among influenza-like illness outpatients tested between September and December 2025. Among 9,579 participants, sequencing of 316 randomly selected A(H3N2)-positive samples showed 84.8% were subclade K, and antigenic analysis of 65 viruses indicated antigenic divergence. Despite this, adjusted VE against laboratory-confirmed influenza was 41.3% (95% CI: 29.2 to 51.3), indicating moderate protection during this subclade K-dominated season.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Shen Y, Zhang D, Feng Z, et al. Moderate protection from vaccination against influenza A(H3N2) subclade K in Beijing, China, September to December 2025. Euro Surveill. 2026. PMID: 41540926. doi:10.2807/1560-7917.ES.2026.31.2.2500993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。